Primary Purpose
| primary_purpose | Study_Count |
|---|---|
| Treatment | 85 |
| Other | 5 |
| NA | 4 |
| Prevention | 3 |
| Basic Science | 2 |
| Diagnostic | 2 |
| Screening | 1 |
| Supportive Care | 1 |
Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD
See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG
To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html
| Type | Study_count |
|---|---|
| Total_Studies | 165 |
| interventional | 103 |
| Observational | 59 |
| Registry | 3 |
```
| intervention_type | Study_Count |
|---|---|
| Drug | 46 |
| Biological | 37 |
| Drug|placebo | 6 |
| Genetic | 5 |
| Other | 3 |
| Behavioral | 1 |
| Device | 1 |
| Dietary Supplement | 1 |
| Drug|Genetic | 1 |
| Drug|Other | 1 |
| Procedure | 1 |
| Country | Study_Count |
|---|---|
| United States | 12 |
| United Kingdom | 6 |
| China | 4 |
| France | 3 |
| NA | 3 |
| India | 2 |
| Spain | 2 |
| United States|Australia | 2 |
| United States|Bulgaria|Russian Federation|Switzerland|United Kingdom | 2 |
| Argentina|Brazil|Bulgaria|Chile|Colombia|Czechia|India|Ireland|Italy|Japan|Poland|Romania|Russian Federation|Sweden|Taiwan|Ukraine|United Kingdom | 1 |
| Argentina|Brazil|Bulgaria|Chile|Colombia|Czechia|Poland|Romania|Russian Federation|Ukraine | 1 |
| Armenia|Georgia|Poland|Russian Federation|South Africa | 1 |
| Australia|Austria|Canada|Czech Republic|France|Germany|Israel|Italy|Russian Federation|Spain | 1 |
| Austria|Denmark|Germany|Italy|Malaysia|South Africa|Spain|Sweden|Switzerland|Thailand|United Kingdom | 1 |
| Austria|France|Germany|Hungary|Israel|Italy|Spain|Turkey | 1 |
| Austria|France|Germany|Israel|Italy|Spain | 1 |
| Belgium | 1 |
| Brazil | 1 |
| Bulgaria | 1 |
| Bulgaria|Canada|Croatia|Korea, Republic of|Malaysia|Mexico|Poland|Singapore|Turkey | 1 |
| Bulgaria|Germany|Japan|Ukraine|United Kingdom | 1 |
| Bulgaria|Israel | 1 |
| Bulgaria|Russian Federation | 1 |
| Canada | 1 |
| Chile|Argentina|Bulgaria|Colombia|Czechia|Poland|Romania|Russian Federation|Ukraine|United Kingdom | 1 |
| Colombia|Czechia|Japan|Poland|Romania|Chile|Argentina|Brazil|Bulgaria|Russian Federation|Spain|Sweden|Ukraine|United Kingdom | 1 |
| Denmark|Germany|Netherlands | 1 |
| France|Germany|Israel | 1 |
| France|Hungary|Israel|Poland|Spain|Turkey|United Kingdom | 1 |
| Georgia|Moldova, Republic of|United Kingdom | 1 |
| Germany|Greece|Italy|Spain|United Kingdom | 1 |
| Germany|Japan|Spain | 1 |
| India|Poland|Romania|Russian Federation|Ukraine|United Kingdom | 1 |
| Israel | 1 |
| Korea, Republic of | 1 |
| Moldova, Republic of|South Africa|Ukraine | 1 |
| Netherlands | 1 |
| Poland|Romania|Russian Federation | 1 |
| Poland|South Africa|United Kingdom | 1 |
| Poland|Ukraine | 1 |
| Poland|United Kingdom | 1 |
| South Africa | 1 |
| Spain|Sweden|United States|Austria|Canada|Croatia|Denmark|Greece|Israel|Italy|Japan|Malaysia|Ukraine|United Kingdom | 1 |
| United States|Algeria|Argentina|Australia|Austria|Canada|France|Germany|Israel|Italy|Japan|Malaysia|Netherlands|Spain|Taiwan|Thailand|United Kingdom | 1 |
| United States|Argentina|Brazil|Bulgaria|France|Philippines|Poland|Romania|Russian Federation|South Africa|Spain|Turkey | 1 |
| United States|Argentina|Brazil|Canada|Croatia|France|Hungary|Israel|Italy|Japan|Malaysia|Poland|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom | 1 |
| United States|Australia|Austria|Bulgaria|Canada|Czechia|France|Germany|Israel|Italy|Japan|Malaysia|Philippines|South Africa|Spain | 1 |
| United States|Australia|Belgium|Brazil|Canada|China|France|Germany|Hong Kong|India|Ireland|Italy|Japan|Netherlands|Poland|South Africa|Sweden|United Kingdom | 1 |
| United States|Australia|Belgium|Brazil|Canada|China|France|Germany|Hong Kong|India|Italy|Japan|Poland|Russian Federation|South Africa|Sweden|United Kingdom | 1 |
| United States|Australia|Belgium|Brazil|Canada|France|Germany|Greece|Israel|Italy|Japan|Korea, Republic of|Saudi Arabia|Spain|Sweden|Taiwan|Turkey|United Kingdom | 1 |
| United States|Australia|Belgium|Denmark|France|Germany|Ireland|Italy|Netherlands|New Zealand|Poland|Spain|Sweden|Switzerland|United Kingdom | 1 |
| United States|Australia|Brazil|Bulgaria|Chile|China|Colombia|Denmark|France|Germany|Hungary|India|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|New Zealand|Poland|Romania|Russian Federation|Singapore|South Africa|Sweden|Taiwan|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Canada|China|France|Germany|India|Italy|Japan|Korea, Republic of|Malaysia|South Africa|Spain|Taiwan|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Canada|Greece|Japan|Saudi Arabia|Sweden|Taiwan|Turkey|United Kingdom | 1 |
| United States|Australia|China|Denmark|France|Germany|Hungary|India|Israel|Italy|Japan|Korea, Republic of|Malaysia|South Africa|Spain|Taiwan|Turkey|Ukraine|United Kingdom | 1 |
| United States|Australia|Ireland|Netherlands|South Africa|United Kingdom | 1 |
| United States|Austria|Brazil|Croatia|Greece|Hungary|Italy|Japan|Malaysia|Poland|Puerto Rico|Romania|Russian Federation|Serbia|South Africa|Taiwan|Thailand|Turkey|United Kingdom | 1 |
| United States|Austria|Bulgaria|France|Germany|Israel|Italy|Japan|Russian Federation|Spain | 1 |
| United States|Austria|France|Germany|Greece|Italy|Japan|Macedonia, The Former Yugoslav Republic of|Malaysia|Netherlands|Romania|Russian Federation|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom | 1 |
| United States|Austria|France|Germany|Greece|Italy|Japan|Macedonia, The Former Yugoslav Republic of|Malaysia|Netherlands|Romania|South Africa|Spain|Taiwan|Thailand|Turkey|United Kingdom | 1 |
| United States|Belarus|Bulgaria|Georgia|Israel|Poland|Romania|Russian Federation|Ukraine|United Kingdom | 1 |
| United States|Belgium|Denmark|Germany|Ireland|Italy|Netherlands|Sweden|United Kingdom | 1 |
| United States|Brazil|Bulgaria|Croatia|Japan|New Zealand|Poland|Romania|Russian Federation|Ukraine | 1 |
| United States|Brazil|Canada|Croatia|France|Germany|Italy|Japan|Malaysia|Taiwan|United Kingdom | 1 |
| United States|Brazil|Former Serbia and Montenegro|France|Japan|Malaysia|Serbia|South Africa|Sweden|Turkey|United Kingdom | 1 |
| United States|Bulgaria|Hong Kong|India|Japan|Korea, Republic of|Russian Federation|Spain|Taiwan|Turkey | 1 |
| United States|Canada|Croatia|Hungary|Italy|Romania|Russian Federation|Serbia|Spain | 1 |
| United States|Canada|France|Germany|Hungary|Italy|Japan|Macedonia, The Former Yugoslav Republic of|Malaysia|Netherlands|Russian Federation|South Africa|Thailand|Turkey|United Kingdom | 1 |
| United States|Denmark|France|Germany|Japan|Spain|Sweden|United Kingdom | 1 |
| United States|Denmark|France|United Kingdom | 1 |
| United States|France|India|Israel|Italy|Poland|United Kingdom | 1 |
| United States|Germany|Switzerland | 1 |
| United States|Greece|Japan|Malaysia|Romania|Serbia|Thailand | 1 |
| United States|Italy|United Kingdom | 1 |
| United States|Japan|Poland|Romania|Russian Federation|Serbia|Spain|Taiwan|Ukraine | 1 |
| United States|United Kingdom | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 20 |
| 2 | 2 |
| 3 | 6 |
| 4 | 3 |
| 5 | 4 |
| 6 | 4 |
| 7 | 8 |
| 8 | 3 |
| 9 | 1 |
| 10 | 3 |
| 11 | 2 |
| 12 | 1 |
| 14 | 3 |
| 15 | 4 |
| 16 | 3 |
| 17 | 5 |
| 18 | 2 |
| 19 | 2 |
| 20 | 2 |
| 22 | 1 |
| 23 | 1 |
| 24 | 1 |
| 25 | 2 |
| 30 | 1 |
| 32 | 1 |
| 34 | 1 |
| 37 | 2 |
| 39 | 1 |
| 41 | 1 |
| 42 | 2 |
| 43 | 1 |
| 45 | 1 |
| 49 | 2 |
| 51 | 1 |
| 58 | 1 |
| 61 | 2 |
| 64 | 3 |
| Phase | Study_Count |
|---|---|
| Phase 3 | 36 |
| Phase 1 | 26 |
| Phase 4 | 12 |
| Phase 2 | 11 |
| Phase 1/Phase 2 | 8 |
| N/A | 5 |
| Phase 2/Phase 3 | 5 |
| Number_of_Arms | Count_of_Studies |
|---|---|
| 1 | 43 |
| 2 | 29 |
| 3 | 13 |
| 4 | 4 |
| 5 | 1 |
| 6 | 2 |
| 9 | 1 |
| 10 | 1 |
| NA | 9 |
| Measure | N.A | Phase.1 | Phase.1.Phase.2 | Phase.2 | Phase.2.Phase.3 | Phase.3 | Phase.4 |
|---|---|---|---|---|---|---|---|
| Min. | 3.0 | 6.00000 | 3.000 | 3.00000 | 10.0 | 13.00000 | 1.00000 |
| 1st Qu. | 14.0 | 12.00000 | 15.250 | 12.00000 | 23.0 | 27.75000 | 13.75000 |
| Median | 20.0 | 16.00000 | 24.000 | 19.00000 | 50.0 | 53.00000 | 27.50000 |
| Mean | 132.4 | 20.38462 | 24.625 | 19.09091 | 44.6 | 65.03333 | 32.83333 |
| 3rd Qu. | 25.0 | 27.25000 | 31.750 | 23.00000 | 63.0 | 83.00000 | 45.75000 |
| Max. | 600.0 | 52.00000 | 52.000 | 51.00000 | 77.0 | 250.00000 | 70.00000 |
| group_type | Group_Count |
|---|---|
| Experimental | 164 |
| Active Comparator | 16 |
| NA | 9 |
| Other | 8 |
| Placebo Comparator | 4 |
| intervention_model | Study_Count |
|---|---|
| Single Group Assignment | 50 |
| Parallel Assignment | 23 |
| Crossover Assignment | 14 |
| NA | 8 |
| Sequential Assignment | 7 |
| Factorial Assignment | 1 |
| primary_purpose | Study_Count |
|---|---|
| Treatment | 85 |
| Other | 5 |
| NA | 4 |
| Prevention | 3 |
| Basic Science | 2 |
| Diagnostic | 2 |
| Screening | 1 |
| Supportive Care | 1 |
| Country | Study_Count |
|---|---|
| United States | 15 |
| Japan | 5 |
| NA | 4 |
| France | 3 |
| Canada | 2 |
| Korea, Republic of | 2 |
| United Kingdom | 2 |
| Algeria|Austria|Belgium|Czech Republic|France|Germany|Italy|Netherlands|Poland|Portugal|Saudi Arabia|South Africa|Sweden|Turkey|United Kingdom|Venezuela | 1 |
| Algeria|Morocco|Oman|Saudi Arabia|United Arab Emirates | 1 |
| Argentina|Austria|Belgium|France|Germany|Hungary|Iran, Islamic Republic of|Ireland|Italy|Poland|Portugal|Slovakia|Sweden|United Kingdom | 1 |
| Austria|Belgium|France|Germany|Italy|Netherlands|Portugal|Spain|Sweden|United Kingdom | 1 |
| Austria|Canada|Germany|Norway|Portugal | 1 |
| Austria|Germany | 1 |
| Belgium | 1 |
| Belgium|France|Germany|Italy|Spain|Sweden|United Kingdom | 1 |
| Brazil | 1 |
| Brazil|Canada | 1 |
| Canada|Spain|United Kingdom | 1 |
| Denmark|Finland|Sweden | 1 |
| Denmark|Japan | 1 |
| Ecuador | 1 |
| Germany | 1 |
| Greece|Ireland|Italy|Norway|Saudi Arabia|Sweden|United Arab Emirates|United Kingdom | 1 |
| India|Morocco|Oman|South Africa | 1 |
| Netherlands|United Kingdom | 1 |
| Spain | 1 |
| United States|Algeria|Australia|Austria|Bulgaria|Canada|Croatia|Finland|France|Germany|Greece|India|Israel|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Norway|Poland|Portugal|Russian Federation|Serbia|Slovakia|South Africa|Spain|Sweden|Turkey|Ukraine|United Kingdom | 1 |
| United States|Argentina|Canada|Croatia|Czech Republic|France|Germany|Ireland|Italy|Slovakia|Spain|Sweden|Switzerland|United Kingdom | 1 |
| United States|Australia|Germany|Israel|Italy|Japan|Netherlands|Sweden|Taiwan | 1 |
| United States|Austria|Belgium|Canada|France|Germany|Italy|Spain|United Kingdom | 1 |
| United States|Austria|France|Germany|Italy|Spain | 1 |
| United States|Puerto Rico | 1 |
| United States|United Kingdom | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 25 |
| 2 | 3 |
| 3 | 1 |
| 4 | 3 |
| 5 | 6 |
| 9 | 1 |
| 11 | 1 |
| 12 | 2 |
| 14 | 2 |
| 16 | 1 |
| 17 | 2 |
| 18 | 1 |
| 19 | 1 |
| 21 | 2 |
| 22 | 2 |
| 23 | 1 |
| 25 | 1 |
| 27 | 1 |
| 38 | 1 |
| 91 | 1 |
| 136 | 1 |
| Measure | Observational |
|---|---|
| Min | 4.0000 |
| 1st Qu | 37.5000 |
| Median | 86.0000 |
| Mean | 252.2034 |
| 3rd Qu | 266.0000 |
| Max | 2300.0000 |
| observational_model | Study_Count |
|---|---|
| Cohort | 41 |
| Case-Only | 6 |
| NA | 6 |
| Ecologic or Community | 3 |
| Other | 3 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 33 |
| Retrospective | 16 |
| Cross-Sectional | 7 |
| NA | 2 |
| Other | 1 |
| Country | Study_Count |
|---|---|
| Canada | 1 |
| Germany | 1 |
| United States | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 2 |
| 38 | 1 |
| Measure | Registries |
|---|---|
| Min | 66 |
| 1st Qu | 133 |
| Median | 200 |
| Mean | 182 |
| 3rd Qu | 240 |
| Max | 280 |
| observational_model | Study_Count |
|---|---|
| Cohort | 3 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 3 |
| target_duration | Study_Count |
|---|---|
| 4 Years | 1 |
| 5 Years | 1 |
| 7 Days | 1 |
#If less then 500 trials
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT03995784 | Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B | https://ClinicalTrials.gov/show/NCT03995784 | Completed | Catalyst Biosciences | 2020-02-28 |
| NCT03407651 | Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B | https://ClinicalTrials.gov/show/NCT03407651 | Completed | Catalyst Biosciences | 2019-03-15 |
| NCT03369444 | A Factor IX Gene Therapy Study (FIX-GT) | https://ClinicalTrials.gov/show/NCT03369444 | Recruiting | University College, London | 2021-01-01 |
| NCT03307980 | Long-term Safety and Efficacy Study of SPK-9001 in Individuals With Hemophilia B | https://ClinicalTrials.gov/show/NCT03307980 | Recruiting | Pfizer | 2026-10-06 |
| NCT03196284 | A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors | https://ClinicalTrials.gov/show/NCT03196284 | Completed | Novo Nordisk A/S | 2018-09-19 |
| NCT03186677 | Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients | https://ClinicalTrials.gov/show/NCT03186677 | Completed | ISU Abxis Co., Ltd. | 2018-10-10 |
| NCT03075670 | A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B | https://ClinicalTrials.gov/show/NCT03075670 | Completed | Novo Nordisk A/S | 2017-12-08 |
| NCT02695160 | Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B | https://ClinicalTrials.gov/show/NCT02695160 | Active, not recruiting | Sangamo Therapeutics | 2021-01-31 |
| NCT02571569 | A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors | https://ClinicalTrials.gov/show/NCT02571569 | Completed | Bayer | 2018-07-09 |
| NCT02554773 | An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B | https://ClinicalTrials.gov/show/NCT02554773 | Active, not recruiting | Sanofi | 2023-02-28 |
| NCT02541942 | Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adeptâ„¢2 Trial | https://ClinicalTrials.gov/show/NCT02541942 | Completed | Novo Nordisk A/S | 2016-04-15 |
| NCT02484092 | A Gene Therapy Study for Hemophilia B | https://ClinicalTrials.gov/show/NCT02484092 | Completed | Pfizer | 2019-04-08 |
| NCT02418793 | A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B | https://ClinicalTrials.gov/show/NCT02418793 | Completed | OPKO Health, Inc. | 2018-09-30 |
| NCT02396342 | Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B | https://ClinicalTrials.gov/show/NCT02396342 | Active, not recruiting | UniQure Biopharma B.V. | 2021-05-31 |
| NCT02336178 | Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China | https://ClinicalTrials.gov/show/NCT02336178 | Completed | Pfizer | 2016-07-31 |
| NCT02263469 | A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years | https://ClinicalTrials.gov/show/NCT02263469 | Completed | Bio Products Laboratory | 2006-07-31 |
| NCT02263456 | A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B | https://ClinicalTrials.gov/show/NCT02263456 | Completed | Bio Products Laboratory | 2001-09-30 |
| NCT02250573 | An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery | https://ClinicalTrials.gov/show/NCT02250573 | Completed | Bio Products Laboratory | 2006-04-30 |
| NCT02250560 | A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery. | https://ClinicalTrials.gov/show/NCT02250560 | Completed | Bio Products Laboratory | 2003-11-30 |
| NCT02234310 | Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B | https://ClinicalTrials.gov/show/NCT02234310 | Completed | Bioverativ Therapeutics Inc. | 2019-08-20 |
| NCT02231944 | An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients | https://ClinicalTrials.gov/show/NCT02231944 | Completed | Bio Products Laboratory | 2003-10-31 |
| NCT02213250 | An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B | https://ClinicalTrials.gov/show/NCT02213250 | Completed | Pfizer | 2015-04-30 |
| NCT02141074 | Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B | https://ClinicalTrials.gov/show/NCT02141074 | Recruiting | Novo Nordisk A/S | 2022-10-30 |
| NCT01288391 | Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients | https://ClinicalTrials.gov/show/NCT01288391 | Completed | Novo Nordisk A/S | 2011-07-31 |
| NCT01286779 | BAX 326 (rFIX) Continuation Study | https://ClinicalTrials.gov/show/NCT01286779 | Completed | Shire | 2017-06-29 |
| NCT01272206 | Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects | https://ClinicalTrials.gov/show/NCT01272206 | Completed | Novo Nordisk A/S | 2011-03-31 |
| NCT02035605 | A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients | https://ClinicalTrials.gov/show/NCT02035605 | Completed | Alnylam Pharmaceuticals | 2017-07-20 |
| NCT02020369 | Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors | https://ClinicalTrials.gov/show/NCT02020369 | Completed | rEVO Biologics | 2015-07-31 |
| NCT01949792 | A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors | https://ClinicalTrials.gov/show/NCT01949792 | Completed | Novo Nordisk A/S | 2013-11-30 |
| NCT01921855 | Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors | https://ClinicalTrials.gov/show/NCT01921855 | Completed | Bayer | 2009-12-31 |
| NCT01757405 | Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen | https://ClinicalTrials.gov/show/NCT01757405 | Completed | Shire | 2014-11-11 |
| NCT01748201 | Viscosupplementation in Patients With Hemophilic Arthropathy | https://ClinicalTrials.gov/show/NCT01748201 | Completed | University of Sao Paulo General Hospital | 2013-03-31 |
| NCT01687608 | Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B | https://ClinicalTrials.gov/show/NCT01687608 | Active, not recruiting | Shire | 2030-10-28 |
| NCT01662531 | A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B | https://ClinicalTrials.gov/show/NCT01662531 | Completed | CSL Behring | 2014-10-31 |
| NCT01625390 | A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150 | https://ClinicalTrials.gov/show/NCT01625390 | Completed | Bayer | 2014-03-31 |
| NCT01563471 | Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers | https://ClinicalTrials.gov/show/NCT01563471 | Completed | Novo Nordisk A/S | 2002-07-31 |
| NCT01562587 | Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State | https://ClinicalTrials.gov/show/NCT01562587 | Completed | Novo Nordisk A/S | 2003-05-31 |
| NCT01561924 | Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography | https://ClinicalTrials.gov/show/NCT01561924 | Completed | Novo Nordisk A/S | 2006-05-31 |
| NCT01561417 | Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects | https://ClinicalTrials.gov/show/NCT01561417 | Completed | Novo Nordisk A/S | 2006-09-30 |
| NCT01561391 | Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery | https://ClinicalTrials.gov/show/NCT01561391 | Completed | Novo Nordisk A/S | 2004-05-31 |
| NCT01555749 | Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects | https://ClinicalTrials.gov/show/NCT01555749 | Completed | Novo Nordisk A/S | 2012-05-08 |
| NCT01507896 | BAX 326 Surgery Study in Hemophilia B Patients | https://ClinicalTrials.gov/show/NCT01507896 | Completed | Shire | 2014-05-15 |
| NCT01496274 | A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B | https://ClinicalTrials.gov/show/NCT01496274 | Completed | CSL Behring | 2014-07-31 |
| NCT01488994 | BAX 326 Pediatric Study | https://ClinicalTrials.gov/show/NCT01488994 | Completed | Shire | 2013-05-14 |
| NCT01467427 | Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. | https://ClinicalTrials.gov/show/NCT01467427 | Active, not recruiting | Novo Nordisk A/S | 2014-03-30 |
| NCT01440946 | Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B | https://ClinicalTrials.gov/show/NCT01440946 | Completed | Bioverativ Therapeutics Inc. | 2014-11-30 |
| NCT01425723 | Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B | https://ClinicalTrials.gov/show/NCT01425723 | Completed | Bioverativ Therapeutics Inc. | 2017-10-31 |
| NCT01395810 | Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 | https://ClinicalTrials.gov/show/NCT01395810 | Completed | Novo Nordisk A/S | 2014-03-30 |
| NCT01392547 | Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors | https://ClinicalTrials.gov/show/NCT01392547 | Completed | Novo Nordisk A/S | 2012-08-31 |
| NCT01386528 | Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B | https://ClinicalTrials.gov/show/NCT01386528 | Completed | Novo Nordisk A/S | 2013-12-01 |
| NCT01361126 | A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B | https://ClinicalTrials.gov/show/NCT01361126 | Completed | CSL Behring | 2012-06-30 |
| NCT01335061 | Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B | https://ClinicalTrials.gov/show/NCT01335061 | Completed | Pfizer | 2014-04-30 |
| NCT01333111 | Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients | https://ClinicalTrials.gov/show/NCT01333111 | Completed | Novo Nordisk A/S | 2013-03-31 |
| NCT04394286 | A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects | https://ClinicalTrials.gov/show/NCT04394286 | Recruiting | Shire | 2024-03-16 |
| NCT04286412 | Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophelia B | https://ClinicalTrials.gov/show/NCT04286412 | Recruiting | Pfizer | 2020-11-05 |
| NCT04135300 | Gene Therapy for Chinese Hemophilia B | https://ClinicalTrials.gov/show/NCT04135300 | Recruiting | Institute of Hematology & Blood Diseases Hospital | 2021-06-30 |
| NCT04073498 | The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B) | https://ClinicalTrials.gov/show/NCT04073498 | Recruiting | ApcinteX Ltd | 2021-04-30 |
| NCT04072237 | Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia | https://ClinicalTrials.gov/show/NCT04072237 | Active, not recruiting | Catalyst Biosciences | 2020-04-30 |
| NCT03861273 | A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B | https://ClinicalTrials.gov/show/NCT03861273 | Recruiting | Pfizer | 2021-11-26 |
| NCT03855280 | Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B | https://ClinicalTrials.gov/show/NCT03855280 | Recruiting | Medexus Pharma, Inc. | 2021-08-01 |
| NCT03641703 | A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy | https://ClinicalTrials.gov/show/NCT03641703 | Recruiting | Freeline Therapeutics | 2035-12-31 |
| NCT03615053 | Personalized Medicine for Canadians With Hemophilia | https://ClinicalTrials.gov/show/NCT03615053 | Recruiting | McMaster University | 2021-09-30 |
| NCT03587116 | Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) | https://ClinicalTrials.gov/show/NCT03587116 | Recruiting | Pfizer | 2021-09-24 |
| NCT03569891 | HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients | https://ClinicalTrials.gov/show/NCT03569891 | Active, not recruiting | UniQure Biopharma B.V. | 2020-09-30 |
| NCT03507582 | Virtual Reality for Hemophilia | https://ClinicalTrials.gov/show/NCT03507582 | Completed | Nationwide Children’s Hospital | 2016-12-28 |
| NCT03489291 | Dose Confirmation Trial of AAV5-hFIXco-Padua | https://ClinicalTrials.gov/show/NCT03489291 | Active, not recruiting | UniQure Biopharma B.V. | 2018-10-30 |
| NCT03481946 | A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia | https://ClinicalTrials.gov/show/NCT03481946 | Completed | Bayer | 2018-10-17 |
| NCT03417245 | A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors | https://ClinicalTrials.gov/show/NCT03417245 | Active, not recruiting | Sanofi | 2021-04-30 |
| NCT03417102 | A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors | https://ClinicalTrials.gov/show/NCT03417102 | Active, not recruiting | Sanofi | 2020-12-31 |
| NCT01233440 | Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B | https://ClinicalTrials.gov/show/NCT01233440 | Completed | CSL Behring | 2011-07-31 |
| NCT01228669 | Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B | https://ClinicalTrials.gov/show/NCT01228669 | Completed | Novo Nordisk A/S | 2012-09-10 |
| NCT01174446 | Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients | https://ClinicalTrials.gov/show/NCT01174446 | Completed | Shire | 2012-05-03 |
| NCT01128881 | IMMUNINE Pre-Treatment Study | https://ClinicalTrials.gov/show/NCT01128881 | Completed | Shire | 2012-08-31 |
| NCT01090206 | Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia | https://ClinicalTrials.gov/show/NCT01090206 | Completed | Virginia Commonwealth University | 2013-03-31 |
| NCT01027364 | Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B | https://ClinicalTrials.gov/show/NCT01027364 | Completed | Bioverativ Therapeutics Inc. | 2012-07-31 |
| NCT00979238 | Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B | https://ClinicalTrials.gov/show/NCT00979238 | Active, not recruiting | St. Jude Children’s Research Hospital | 2032-06-12 |
| NCT00956345 | Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B | https://ClinicalTrials.gov/show/NCT00956345 | Completed | Novo Nordisk A/S | 2010-07-31 |
| NCT00951873 | A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers | https://ClinicalTrials.gov/show/NCT00951873 | Completed | Novo Nordisk A/S | 2010-04-30 |
| NCT00951405 | Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors | https://ClinicalTrials.gov/show/NCT00951405 | Completed | Novo Nordisk A/S | 2011-03-29 |
| NCT00922792 | Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B | https://ClinicalTrials.gov/show/NCT00922792 | Completed | Novo Nordisk A/S | 2009-09-30 |
| NCT00866606 | Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects | https://ClinicalTrials.gov/show/NCT00866606 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-12-31 |
| NCT00851721 | Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor | https://ClinicalTrials.gov/show/NCT00851721 | Completed | Shire | 2012-10-31 |
| NCT01562457 | Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State | https://ClinicalTrials.gov/show/NCT01562457 | Completed | Novo Nordisk A/S | 2006-04-30 |
| NCT03938792 | Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B | https://ClinicalTrials.gov/show/NCT03938792 | Recruiting | Pfizer | 2023-04-27 |
| NCT02053792 | A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B | https://ClinicalTrials.gov/show/NCT02053792 | Active, not recruiting | CSL Behring | 2021-09-30 |
| NCT03091751 | Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B | https://ClinicalTrials.gov/show/NCT03091751 | Completed | Grifols Biologicals, LLC | 2009-10-31 |
| NCT03565237 | RIXUBIS PMS India (RIXUBIS PMS) | https://ClinicalTrials.gov/show/NCT03565237 | Recruiting | Shire | 2021-04-21 |
| NCT00768287 | Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B | https://ClinicalTrials.gov/show/NCT00768287 | Completed | Aptevo Therapeutics | 2013-03-31 |
| NCT00749476 | Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX | https://ClinicalTrials.gov/show/NCT00749476 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-01-31 |
| NCT00716716 | Phase I/IIa Study of FIXFc in Hemophilia B Patients | https://ClinicalTrials.gov/show/NCT00716716 | Completed | Bioverativ Therapeutics Inc. | 2009-10-31 |
| NCT00638001 | Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy | https://ClinicalTrials.gov/show/NCT00638001 | Completed | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2012-03-31 |
| NCT00581126 | Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B | https://ClinicalTrials.gov/show/NCT00581126 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | NA |
| NCT00571584 | High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors | https://ClinicalTrials.gov/show/NCT00571584 | Completed | Novo Nordisk A/S | 2004-03-31 |
| NCT00486278 | Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds | https://ClinicalTrials.gov/show/NCT00486278 | Completed | Novo Nordisk A/S | 2010-06-30 |
| NCT00364182 | Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B | https://ClinicalTrials.gov/show/NCT00364182 | Completed | Pfizer | 2010-10-31 |
| NCT00212459 | The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs | https://ClinicalTrials.gov/show/NCT00212459 | Completed | New York Presbyterian Hospital | 2006-02-28 |
| NCT00139828 | Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX) | https://ClinicalTrials.gov/show/NCT00139828 | Completed | Sanquin Plasma Products BV | NA |
| NCT00108797 | Trial of NovoSeven® in Haemophilia - Joint Bleeds | https://ClinicalTrials.gov/show/NCT00108797 | Completed | Novo Nordisk A/S | 2006-02-28 |
| NCT00108758 | Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia | https://ClinicalTrials.gov/show/NCT00108758 | Completed | Novo Nordisk A/S | 2005-11-30 |
| NCT00093210 | Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B | https://ClinicalTrials.gov/show/NCT00093210 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | NA |
| NCT00093171 | Study Evaluating rFIX; BeneFIX® in Hemophilia B | https://ClinicalTrials.gov/show/NCT00093171 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-05-31 |
| NCT00037557 | Study Evaluating rFIX; BeneFIX in Severe Hemophilia B | https://ClinicalTrials.gov/show/NCT00037557 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | NA |
| NCT00004801 | Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency | https://ClinicalTrials.gov/show/NCT00004801 | Completed | Office of Rare Diseases (ORD) | NA |
#If less then 500 studies
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT03358836 | Joint Health Study | https://ClinicalTrials.gov/show/NCT03358836 | Active, not recruiting | Bloodworks | 2027-12-31 |
| NCT03276130 | Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B | https://ClinicalTrials.gov/show/NCT03276130 | Recruiting | Swedish Orphan Biovitrum | 2019-12-31 |
| NCT03185897 | Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia | https://ClinicalTrials.gov/show/NCT03185897 | Active, not recruiting | Shire | 2022-04-30 |
| NCT03054389 | Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews | https://ClinicalTrials.gov/show/NCT03054389 | Completed | Shire | 2017-06-06 |
| NCT02937831 | RIXUBIS Drug Use-Result Survey (Japan) | https://ClinicalTrials.gov/show/NCT02937831 | Recruiting | Shire | 2021-04-30 |
| NCT02922231 | Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea | https://ClinicalTrials.gov/show/NCT02922231 | Completed | Shire | 2019-04-04 |
| NCT00835068 | Post Marketing Observational Study of Reformulated BeneFIX | https://ClinicalTrials.gov/show/NCT00835068 | Completed | Pfizer | 2013-10-31 |
| NCT02807753 | The Hemophilia Ultrasound Project | https://ClinicalTrials.gov/show/NCT02807753 | Recruiting | University of Miami | 2021-07-31 |
| NCT02740413 | Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study | https://ClinicalTrials.gov/show/NCT02740413 | Completed | Pfizer | 2017-12-31 |
| NCT02634918 | Ultrasonography in Hemophilic Joint Disease and Serum Markers | https://ClinicalTrials.gov/show/NCT02634918 | Completed | Northwell Health | 2019-08-31 |
| NCT02502409 | Natural History Study of Factor IX Treatment and Complications | https://ClinicalTrials.gov/show/NCT02502409 | Active, not recruiting | Skane University Hospital | 2019-06-30 |
| NCT02300519 | Thrombin Generation Numerical Models Validation in Haemophilic Case | https://ClinicalTrials.gov/show/NCT02300519 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 2015-07-31 |
| NCT02241694 | To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives | https://ClinicalTrials.gov/show/NCT02241694 | Completed | Novo Nordisk A/S | 2015-07-31 |
| NCT02190149 | Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS | https://ClinicalTrials.gov/show/NCT02190149 | Completed | Shire | 2016-03-31 |
| NCT02049099 | A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care | https://ClinicalTrials.gov/show/NCT02049099 | Completed | Swedish Orphan Biovitrum | 2015-09-30 |
| NCT01988532 | Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia | https://ClinicalTrials.gov/show/NCT01988532 | Completed | Novo Nordisk A/S | 2014-10-31 |
| NCT01959555 | Project to Update the Study of Congenital Haemophilia in Spain | https://ClinicalTrials.gov/show/NCT01959555 | Completed | Novo Nordisk A/S | 2014-12-31 |
| NCT01830712 | A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors | https://ClinicalTrials.gov/show/NCT01830712 | Completed | Novo Nordisk A/S | 2011-08-31 |
| NCT01589848 | Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador | https://ClinicalTrials.gov/show/NCT01589848 | Completed | Universidad del Azuay | 2013-06-30 |
| NCT01586936 | Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors | https://ClinicalTrials.gov/show/NCT01586936 | Completed | Novo Nordisk A/S | 2010-03-09 |
| NCT01579968 | Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery | https://ClinicalTrials.gov/show/NCT01579968 | Completed | Novo Nordisk A/S | 2010-03-09 |
| NCT01579955 | Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice | https://ClinicalTrials.gov/show/NCT01579955 | Completed | Novo Nordisk A/S | 2010-03-09 |
| NCT01510418 | Socialization of Adult Men With Congenital Hemophilia A or B | https://ClinicalTrials.gov/show/NCT01510418 | Completed | Dana-Farber Cancer Institute | 2013-05-31 |
| NCT01503567 | Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries | https://ClinicalTrials.gov/show/NCT01503567 | Completed | Novo Nordisk A/S | 2012-09-30 |
| NCT01322620 | Survey Evaluating the Psychosocial Effects of Living With Haemophilia | https://ClinicalTrials.gov/show/NCT01322620 | Completed | Novo Nordisk A/S | 2012-02-29 |
| NCT03875547 | Post-marketing Surveillance (Use Result Surveillance) With Refixia® | https://ClinicalTrials.gov/show/NCT03875547 | Enrolling by invitation | Novo Nordisk A/S | 2025-09-30 |
| NCT03818529 | ATHN 8: PUPs Matter Study | https://ClinicalTrials.gov/show/NCT03818529 | Recruiting | American Thrombosis and Hemostasis Network | 2023-03-31 |
| NCT03690336 | Adverse Event Data Collection From External Registries on Nonacog Beta Pegol | https://ClinicalTrials.gov/show/NCT03690336 | Enrolling by invitation | Novo Nordisk A/S | 2027-10-01 |
| NCT03655340 | A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France | https://ClinicalTrials.gov/show/NCT03655340 | Active, not recruiting | Swedish Orphan Biovitrum | 2021-09-30 |
| NCT03430154 | Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE) | https://ClinicalTrials.gov/show/NCT03430154 | Completed | Novo Nordisk A/S | 2018-04-29 |
| NCT01234545 | Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors | https://ClinicalTrials.gov/show/NCT01234545 | Completed | Novo Nordisk A/S | 2012-04-30 |
| NCT01220141 | Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B | https://ClinicalTrials.gov/show/NCT01220141 | Completed | Novo Nordisk A/S | 2015-03-31 |
| NCT01217255 | Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World | https://ClinicalTrials.gov/show/NCT01217255 | Completed | The Hospital for Sick Children | 2013-10-31 |
| NCT01154231 | BeneFIX Drug Use Results Survey [All-Case Surveillance] | https://ClinicalTrials.gov/show/NCT01154231 | Completed | Pfizer | 2014-08-31 |
| NCT00936845 | Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study | https://ClinicalTrials.gov/show/NCT00936845 | Completed | Weill Medical College of Cornell University | 2010-01-31 |
| NCT00936312 | Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study | https://ClinicalTrials.gov/show/NCT00936312 | Completed | Weill Medical College of Cornell University | 2011-08-31 |
| NCT00927992 | Study Evaluating Liver Transplantation in Haemophilia Patients in Spain | https://ClinicalTrials.gov/show/NCT00927992 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2010-06-30 |
| NCT00882778 | PROPACT: Retrospective Prophylaxis Patient Case Collection | https://ClinicalTrials.gov/show/NCT00882778 | Completed | Novo Nordisk A/S | 2010-05-31 |
| NCT00853086 | Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database | https://ClinicalTrials.gov/show/NCT00853086 | Completed | Novo Nordisk A/S | 2011-06-30 |
| NCT03901755 | An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B | https://ClinicalTrials.gov/show/NCT03901755 | Recruiting | Swedish Orphan Biovitrum | 2023-03-31 |
| NCT03660774 | A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia | https://ClinicalTrials.gov/show/NCT03660774 | Completed | Novo Nordisk A/S | 2019-10-11 |
| NCT03533504 | Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability | https://ClinicalTrials.gov/show/NCT03533504 | Enrolling by invitation | McMaster University | 2024-06-30 |
| NCT03055611 | A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B | https://ClinicalTrials.gov/show/NCT03055611 | Active, not recruiting | Swedish Orphan Biovitrum | 2022-04-30 |
| NCT02568202 | Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) | https://ClinicalTrials.gov/show/NCT02568202 | Completed | Novo Nordisk A/S | 2015-11-30 |
| NCT00824798 | Gait Evaluation in Haemophiliac Patients | https://ClinicalTrials.gov/show/NCT00824798 | Completed | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2011-01-31 |
| NCT02938156 | UK - EHL Outcomes Registry | https://ClinicalTrials.gov/show/NCT02938156 | Recruiting | Royal Free Hospital NHS Foundation Trust | 2019-10-31 |
| NCT02971969 | Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B | https://ClinicalTrials.gov/show/NCT02971969 | Active, not recruiting | Ultragenyx Pharmaceutical Inc | 2022-02-18 |
| NCT02796222 | Factor Product Utilization and Health Outcomes in Patients With Hemophilia | https://ClinicalTrials.gov/show/NCT02796222 | Recruiting | University of British Columbia | 2019-12-31 |
| NCT03745924 | A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN | https://ClinicalTrials.gov/show/NCT03745924 | Enrolling by invitation | Novo Nordisk A/S | 2027-12-15 |
| NCT03741881 | A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorerâ„¢6) | https://ClinicalTrials.gov/show/NCT03741881 | Enrolling by invitation | Novo Nordisk A/S | 2021-03-17 |
| NCT00714415 | Registry For Patients Treated With BeneFix In Usual Care Setting In Germany | https://ClinicalTrials.gov/show/NCT00714415 | Completed | Pfizer | 2016-10-31 |
| NCT00710619 | Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX | https://ClinicalTrials.gov/show/NCT00710619 | Completed | Novo Nordisk A/S | 2009-07-31 |
| NCT00703911 | Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors | https://ClinicalTrials.gov/show/NCT00703911 | Completed | Novo Nordisk A/S | 2010-07-31 |
| NCT00581438 | Study Evaluating Approach to Treatment of Haemophilia A and B in Spain | https://ClinicalTrials.gov/show/NCT00581438 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2007-12-31 |
| NCT00515710 | LTFU for Gene Transfer Subjects With Hemophilia B | https://ClinicalTrials.gov/show/NCT00515710 | Completed | Spark Therapeutics | 2017-12-31 |
| NCT00484185 | Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B | https://ClinicalTrials.gov/show/NCT00484185 | Completed | Pfizer | 2012-06-30 |
| NCT00244114 | Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients | https://ClinicalTrials.gov/show/NCT00244114 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-12-31 |
| NCT00195221 | Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B | https://ClinicalTrials.gov/show/NCT00195221 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | NA |
| NCT00167973 | Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use | https://ClinicalTrials.gov/show/NCT00167973 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-06-30 |
#If less then 500 registries
| nct_id | brief_title | link | overall_status | source | primary_completion_date |
|---|---|---|---|---|---|
| NCT02912143 | German Pediatric Hemophilia Research Database | https://ClinicalTrials.gov/show/NCT02912143 | Recruiting | Ludwig-Maximilians - University of Munich | 2022-01-01 |
| NCT02199717 | An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia | https://ClinicalTrials.gov/show/NCT02199717 | Completed | The Hospital for Sick Children | 2014-07-31 |
| NCT03619863 | ATHN 7: Hemophilia Natural History Study | https://ClinicalTrials.gov/show/NCT03619863 | Recruiting | American Thrombosis and Hemostasis Network | 2023-09-30 |